Immunome (IMNM) Shares Outstanding (Weighted Average) (2019 - 2026)

Immunome has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $113.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 42.47% year-over-year to $113.1 million; the trailing twelve-month figure through Mar 2026 stood at $113.1 million (up 42.47% YoY), and the FY2025 full-year result was $87.4 million, up 48.96% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $113.1 million, up from $87.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $113.1 million in Q1 2026, with the low at $157314.0 in Q1 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $39.4 million across 5 years, with a median of $12.2 million in 2023.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) tumbled 95.88% — and 2025, when it soared 50378.89%.
• Immunome's Shares Outstanding (Weighted Average) stood at $12.1 million in 2022, then plunged by 95.88% to $500000.0 in 2023, then soared by 11627.89% to $58.6 million in 2024, then soared by 48.96% to $87.4 million in 2025, then gained by 29.52% to $113.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $113.1 million (Q1 2026), $87.4 million (Q4 2025), and $88.0 million (Q3 2025), per Business Quant data.